文献速递胸部肿瘤

miR-17下调LKB1识别预后更差且适合能量应激治疗的NSCLC患者

LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress-Based Treatments.
PubMed 文献 · J Thorac Oncol · 2021-04-19

该研究在NSCLC细胞系和PDX中探索miR-17对LKB1的表观调控及代谢应激治疗敏感性。发现miR-17靶向LKB1 3'UTR,高表达 miR-17 的 LKB1WT 细胞和 PDX 在二甲双胍下凋亡增加;回顾性分析显示 miR-17 与 LKB1 表达负相关,且 miR-17 在 LKB1WT 患者中有预后意义。

要点

  • miR-17是NSCLC中LKB1的表观调控因子,可功能性地损害LKB1/AMPK通路。
  • 在LKB1WT细胞系和LKB1WT/miR-17高表达PDX中,二甲双胍治疗可诱导凋亡。
  • miR-17表达评分可能用于筛选LKB1WT且预后不良、适合能量应激治疗的患者。

核心结论

  • miR-17是NSCLC肿瘤中LKB1表达的中介因子。
  • miR-17表达评分有望区分LKB1WT且LKB1表达受损、预后不良、适合能量应激治疗的NSCLC患者。

研究设计与样本

  • 研究使用具有不同KRAS突变和LKB1缺失组合的NSCLC细胞系,以及miR-17高表达(LKB1WT/miR-17高)或低表达(LKB1WT/miR-17低)的患者来源异种移植瘤(PDX)。
  • 回顾性评估患者NSCLC组织标本和PDX中LKB1与miR-17表达水平。
  • 分析TCGA肺癌数据集中miR-17表达及其与临床特征的潜在相关性。

主要发现

  • 荧光素酶报告实验确认miR-17靶向LKB1 3'非翻译区。
  • miR-17过表达在功能上损害LKB1/AMPK通路。
  • 二甲双胍治疗仅在LKB1WT细胞系和LKB1WT/miR-17高表达PDX中,于miR-17过表达时促使凋亡。
  • 患者NSCLC回顾性分析显示miR-17与LKB1表达呈负相关,并突出miR-17表达在LKB1WT患者中的预后作用。
  • TCGA数据分析进一步证实了miR-17表达在LKB1WT患者中的预后作用。

临床怎么用

  • 对LKB1WT的NSCLC患者,可考虑评估miR-17表达以识别LKB1表达受损和预后不良者。
  • miR-17高表达的LKB1WT患者可能适合基于能量应激的治疗(如二甲双胍相关策略),但需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Preclinical models recently unveiled the vulnerability of LKB1/KRAS comutated NSCLC to metabolic stress-based treatments. Because miR-17 is a potential epigenetic regulator of LKB1, we hypothesized that wild-type LKB1 (LKB1WT) NSCLC with high miR-17 expression may be sensitive to an energetic stress condition, and eligible for metabolic frailties-based therapeutic intervention. METHODS: We took advantage of NSCLC cell lines with different combinations of KRAS mutation and LKB1 deletion and of patient-derived xenografts (PDXs) with high (LKB1WT/miR-17 high) or low (LKB1WT/miR-17 low) miR-17 expression. We evaluated LKB1 pathway impairment and apoptotic response to metformin. We retrospectively evaluated LKB1 and miR-17 expression levels in tissue specimens of patients with NSCLC and PDXs. In addition, a lung cancer series from The Cancer Genome Atlas data set was analyzed for miR-17 expression and potential correlation with clinical features. RESULTS: We identified miR-17 as an epigenetic regulator of LKB1 in NSCLC and confirmed targeting of miR-17 to LKB1 3' untranslated region by luciferase reporter assay. We found that miR-17 overexpression functionally impairs the LKB1/AMPK pathway. Metformin treatment prompted apoptosis on miR-17 overexpression only in LKB1WT cell lines, and in LKB1WT/miR-17 high PDXs. A retrospective analysis in patients with NSCLC revealed an inverse correlation between miR-17 and LKB1 expression and highlighted a prognostic role of miR-17 expression in LKB1WT patients, which was further confirmed by The Cancer Genome Atlas data analysis. CONCLUSIONS: We identified miR-17 as a mediator of LKB1 expression in NSCLC tumors. This study proposes a miR-17 expression score potentially exploitable to discriminate LKB1WT patients with NSCLC with impaired LKB1 expression and poor outcome, eligible for energy-stress-based treatments.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Borzi C, Ganzinelli M, Caiola E, et al. LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress-Based Treatments. J Thorac Oncol. 2021. PMID: 33887464. doi:10.1016/j.jtho.2021.04.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。